Måndag 2 Juni | 20:45:09 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-21 08:00 Kvartalsrapport 2025-Q3
2025-08-29 08:00 Kvartalsrapport 2025-Q2
2025-05-28 - Kvartalsrapport 2025-Q1
2025-05-19 - X-dag ordinarie utdelning ISAB 0.00 SEK
2025-05-16 - Årsstämma
2025-05-08 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-20 - Kvartalsrapport 2024-Q3
2024-09-04 - Extra Bolagsstämma 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2024-05-14 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2023-05-12 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-06-08 - X-dag ordinarie utdelning ISAB 0.00 SEK
2022-05-23 - Kvartalsrapport 2022-Q1
2022-05-06 - Årsstämma
2022-02-28 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-06-22 - Extra Bolagsstämma 2021
2021-06-09 - X-dag ordinarie utdelning ISAB 0.00 SEK
2021-06-08 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-06-12 - Extra Bolagsstämma 2020
2020-05-13 - X-dag ordinarie utdelning ISAB 0.00 SEK
2020-05-12 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-22 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning ISAB 0.00 SEK
2019-02-21 - Bokslutskommuniké 2018
2018-12-13 - Extra Bolagsstämma 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ISAB 0.00 SEK
2018-05-23 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-28 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2025-05-22 08:30:00

Stockholm, May 22, 2025 - Inhalation Sciences AB (ISAB) today announces that the company has entered into a Master Service Agreement (MSA) with the US-based company BioLum Sciences, active in inhalation research and diagnostics. The collaboration aims to strengthen ISAB's commercial presence in the US, increase the availability of the company's technologies and meet the growing demand for advanced in vitro models in line with new regulatory guidelines from the FDA.

BioLum Sciences, based in Dallas, Texas, is an innovative company specializing in the development of novel inhalation diagnostic platforms and oxidative biomarker technologies. Through this collaboration, ISAB's advanced technologies - PreciseInhale® and DissolvIt® - will become more accessible to U.S.-based researchers and drug development clients, enhancing support for preclinical respiratory research and regulatory-aligned development.

The FDA's recently published guidelines for in vitro methods, as well as the fact that the company's in vitro model DissolvIt® was used in a recently completed FDA regulatory study, have led to increased attention and demand for ISAB's technology. This partnership is a strategic step in capitalizing on this demand.

Manoush Masarrat, CEO Inhalation Sciences, comments:

"We see this collaboration as an important step in our expansion in the US. BioLum Sciences shares our vision of replacing animal studies with more precise and ethically defensible methods. With their strong network and scientific expertise, we will be able to meet the increasing demand from US customers who are now adapting to the new FDA guidelines."

Jack Reynolds, CEO of BioLum Sciences, adds:

"We are delighted to be working with Inhalation Sciences. Their technology is cutting edge, and the demand for sophisticated in vitro models is growing rapidly in the U.S. This partnership allows us to address a critical need in respiratory research and together, we will expand preclinical capabilities and offer customers a powerful combination of scientific expertise, advanced technology, and regulatory insight - to accelerate discovery and development."

The new collaboration strengthens ISAB's strategic presence in one of its key growth markets and marks an increased focus on commercial development in line with the company's long-term strategy.

For more information, please contact:

Manoush Masarrat, CEO
Mobile: +46 (0)73 628 9153
E-mail: manoush.masarrat@inhalation.se

Jack Reynolds, CEO
Mobile: (720) 985-3131
E-mail: jpreynolds@biolumsciences.com

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

About BioLum Sciences

BioLum Sciences is a U.S.-based integrated CRO developing advanced diagnostic technologies for real-time measurement of oxidative stress markers, supporting research and clinical development in respiratory, cardiovascular, and other inflammation-driven diseases. BioLum delivers high-sensitivity tools in both early discovery and translational research.